Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12619251 | 1.00 | S1PR1 (0.54) | S1PR1S1PR5S1PR3CYP2C9 | |
| SCHEMBL4523048 | 1.00 | S1PR1 (0.54) | S1PR1S1PR5S1PR3CYP2C9 | |
| SCHEMBL1799522 | 0.94 | S1PR1 (0.61) | S1PR1S1PR5S1PR3CYP2C9 | |
| SCHEMBL1797513 | 0.93 | S1PR1 (0.58) | S1PR1S1PR5S1PR3 | |
| SCHEMBL1798333 | 0.93 | S1PR1 (0.58) | S1PR1S1PR5S1PR3 | |
| SCHEMBL1794737 | 0.92 | S1PR1 (0.60) | S1PR1S1PR5S1PR3CYP2C9 | |
| SCHEMBL12619323 | 0.92 | S1PR1 (0.53) | S1PR1S1PR5S1PR3CYP2C9 | |
| SCHEMBL12619055 | 0.92 | S1PR1 (0.53) | S1PR1S1PR5S1PR3CYP2C9 | |
| SCHEMBL12619336 | 0.92 | S1PR1 (0.54) | S1PR1S1PR5S1PR3CYP2C9 | |
| SCHEMBL12619350 | 0.92 | S1PR1 (0.54) | S1PR1S1PR5S1PR3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2003132-B1 | Oxadiazole derivatives as S1P1 agonists | ASTELLAS PHARMA INC (JP) | 2014-03-05 | — | — | EP | claimed |
| US-7678820-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2010-03-16 | — | — | US | claimed |
| US-20090076070-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-03-19 | — | — | US | claimed |
| EP-2003132-A1 | HETERO COMPOUND | Astellas Pharma Inc. (JP) | 2008-12-17 | — | — | EP | claimed |
| US-7951825-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951825-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100168159-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168159-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-7678820-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2010-03-16 | — | — | US | disclosed |
| US-7678820-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2010-03-16 | — | — | US | disclosed |
| US-20090076070-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090076070-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168159-A1 | HETERO COMPOUND | S1PR1, ENPP2, LPAR1 | S1PR1 1/4885S1PR5 4/4885S1PR3 7/4885 |
| US-20090076070-A1 | HETERO COMPOUND | S1PR1, ENPP2, LPAR1 | S1PR1 1/4885S1PR5 4/4885S1PR3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.